TB-500 Benefits
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
How TB-500 works
TB-500 exerts its biological effects primarily through upregulation of actin, a structural protein critical for cell motility. By sequestering and promoting the polymerization of G-actin (globular actin) into F-actin (filamentous actin), TB-500 enables cells to migrate more effectively toward sites of injury — the foundation of its tissue repair properties (PMID: 20536467). This actin-dependent cell migration drives several downstream effects. Endothelial cells migrate and form new blood vessels (angiogenesis), providing blood supply to damaged tissue. Keratinocytes and fibroblasts migrate into wound beds, accelerating closure. Stem and progenitor cells mobilize from niches to sites of damage, supporting regeneration rather than scar formation. Beyond cell migration, Thymosin Beta-4 acts as an anti-inflammatory and anti-fibrotic agent. It reduces macrophage infiltration, decreases TGF-beta and IL-10 levels, and prevents fibroblast-to-myofibroblast conversion — the process that produces scar tissue (PMID: 36580759). Its N-terminal metabolite Ac-SDKP has been shown to not only prevent but reverse established fibrosis in multiple organ models. In the central nervous system, Thymosin Beta-4 promotes neurogenesis, synaptogenesis, and oligodendrogenesis while suppressing pro-inflammatory signaling — properties that have generated interest for traumatic brain injury research (PMID: 23050817). The pharmacokinetics of TB-500 in humans are not well characterized due to the absence of published human PK studies for the injectable form. Animal data from the 2024 metabolite study (PMID: 38382158) showed that TB-500 is rapidly metabolized into several fragments, with Ac-LK appearing as the primary metabolite at 0-6 hours and Ac-LKK detectable up to 72 hours. The discovery that Ac-LKKTE rather than the parent compound demonstrated wound repair activity raises questions about whether TB-500's effects are direct or metabolite-mediated.
Reported benefits
Based on preliminary research and anecdotal reports, TB-500 has been associated with the following benefits:
- Accelerated wound closure in animal models: increased re-epithelialization, collagen deposition, and new blood vessel formation at injury sites (PMID: 12581423)
- Anti-fibrotic activity across multiple organs: prevents and may reverse fibrosis in liver, lung, heart, and kidney animal models by reducing TGF-beta signaling and blocking myofibroblast conversion (PMID: 36580759)
- Cardiac tissue protection in animal models: reduced infarct size, improved left ventricular function, enhanced cell engraftment, and promoted new blood vessel formation after myocardial infarction (PMID: 34335970, 35712678)
- Human clinical data for dry eye: Phase 2 trial showed 35.1% reduction in ocular discomfort and 59.1% reduction in corneal staining using topical Thymosin Beta-4 eye drops, described as safe and well tolerated (PMID: 25826322)
- Hair growth promotion in mouse models: overexpression led to faster re-growth, higher shaft count, and follicle clustering through VEGF-mediated signaling (PMID: 26083021)
- Anti-inflammatory effects: reduces macrophage infiltration, inflammatory cytokines, and oxidative damage in lung and cardiac tissue animal studies (PMID: 34414534, 35712678)
- Neuroprotective properties in preclinical models: promotes neurogenesis, synaptogenesis, and axonal remodeling in traumatic brain injury models while suppressing neuroinflammation (PMID: 23050817)
- Lung tissue protection: suppressed LPS-induced lung fibrosis by attenuating oxidative injury and inflammasome activation in animal studies (PMID: 34414534)
- Improved flexibility and range of motion reported in peptide communities — attributed to anti-inflammatory and tissue repair mechanisms, though no clinical trial data supports this specific claim
- Commonly stacked with BPC-157 ("Wolverine Stack") for synergistic recovery — no published studies validate this combination, but both peptides target complementary tissue repair pathways
- Hair follicle stem cell activation: exogenous Thymosin Beta-4 promotes migration and differentiation of hair follicle stem cells and accelerates follicle cycle transitions in animal models (PMID: 33393222)
- 2024 metabolite discovery identified Ac-LKKTE as the potentially active compound responsible for wound repair activity, opening new research directions for optimized peptide design (PMID: 38382158)
- Broad biological role: Thymosin Beta-4 comprises 70-80% of all beta-thymosins in the body, with documented roles in wound repair, immune modulation, stem cell differentiation, and organ development (PMID: 36464872)
Supporting research
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice
Wound Repair and Regeneration, 2003 · PMID: 12581423
Foundational study: TB4 significantly increased wound contracture and collagen deposition in diabetic (db/db) and aged mice. A synthetic 7-amino-acid peptide (LKKTETQ) from the actin-binding domain produced comparable wound repair effects to full-length TB4, establishing both the compound and its active fragment as candidates for impaired wound repair.
Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications
Annals of the New York Academy of Sciences, 2010 · PMID: 20536467
Comprehensive review establishing that Tb4 promotes cell migration, blood vessel formation, cell survival, stem cell differentiation, and modulation of inflammatory cytokines. Provided the scientific rationale for dermal, corneal, and cardiac clinical trials.
Thymosin beta4 and the anti-fibrotic switch
International Immunopharmacology, 2023 · PMID: 36580759
Tb4 prevents fibrosis in multiple organ models by reducing macrophage infiltration, decreasing TGF-beta levels, and preventing fibroblast-to-myofibroblast conversion. The N-terminal fragment Ac-SDKP can not only prevent but reverse established fibrosis in liver, lung, heart, and kidney models.
Thymosin beta4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction
Theranostics, 2021 · PMID: 34335970
At 600 ng/mL, Tb4 protected human iPSC-derived cardiomyocytes from hypoxic damage. Combined Tb4 + cardiomyocyte treatment significantly enhanced cell engraftment, induced vasculogenesis, improved left ventricular systolic function, and reduced infarct size in a porcine model. No increased arrhythmias or tumor formation observed.
Thymosin beta4 Protects against Cardiac Damage and Subsequent Cardiac Fibrosis in Mice with Myocardial Infarction
Cardiovascular Therapeutics, 2022 · PMID: 35712678
Exogenous Tb4 substantially decreased oxidative damage, inflammatory markers, cardiac dysfunction, and fibrosis development in mice after myocardial infarction. Tb4 promoted mitochondrial quality control and inhibited myofibroblast activation.
Thymosin Beta-4 Induces Mouse Hair Growth
PLoS One, 2015 · PMID: 26083021
Tb4-overexpressing transgenic mice had faster hair re-growth after depilation, higher number of hair shafts, and hair follicles clustered in groups. Tb4-knockout mice showed significantly slower growth. Mechanism: Tb4 regulates P38/ERK/AKT signaling via VEGF expression.
Multiple potential roles of thymosin beta4 in the growth and development of hair follicles
Journal of Cellular and Molecular Medicine, 2021 · PMID: 33393222
Endogenous Tb4 activates hair follicle cycle transitions and promotes migration and differentiation of hair follicle stem cells. Exogenous Tb4 increases hair growth rate in mice and promotes cashmere production by increasing secondary hair follicle count in goats.
Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial
Cornea, 2015 · PMID: 25826322
Phase 2 RCT in severe dry eye patients including graft-versus-host disease: RGN-259 (0.1% Tb4 eye drops) produced 35.1% reduction in ocular discomfort (P=0.0141) and 59.1% reduction in corneal staining (P=0.0108) versus placebo at day 56. Described as safe and well tolerated. Effects persisted 28 days post-treatment. Note: trial enrolled only 9 patients total.
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model
Clinical Ophthalmology, 2015 · PMID: 26056426
Phase 2 RCT in 72 subjects with moderate-to-severe dry eye: primary endpoints (ocular discomfort and inferior corneal staining at day 29) did not reach statistical significance. However, secondary endpoints showed 27% discomfort reduction in CAE conditions (P=0.0244) and significant improvements in central and superior corneal staining (P=0.0075, P=0.0210). No adverse events reported.
Thymosin beta4 Suppresses LPS-Induced Murine Lung Fibrosis by Attenuating Oxidative Injury and Alleviating Inflammation
Inflammation, 2022 · PMID: 34414534
Tb4 substantially reduced LPS-induced oxidative damage, lung injury, inflammation, and fibrosis in mice. Mechanism: attenuated mitophagy inhibition, inflammasome activation, and TGF-beta1-induced epithelial-mesenchymal transition while suppressing fibroblast proliferation.
Neuroprotective and neurorestorative effects of thymosin beta4 treatment following experimental traumatic brain injury
Annals of the New York Academy of Sciences, 2012 · PMID: 23050817
Tb4 promotes angiogenesis, neurogenesis, synaptogenesis, oligodendrogenesis, and axonal remodeling after traumatic brain injury. Properties include anti-apoptosis, anti-inflammation, and stem cell differentiation. Positioned as a neuroprotective candidate for TBI.
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro
Journal of Chromatography B, 2024 · PMID: 38382158
Only the metabolite Ac-LKKTE showed significant wound repair activity compared to control — not the parent TB-500 compound. Suggests previously reported wound repair activity may be due to Ac-LKKTE rather than the parent form. Ac-LK was the primary metabolite (0-6 hours); Ac-LKK detected up to 72 hours. No toxic effects observed.
Thymosin beta4 and Actin: Binding Modes, Biological Functions and Clinical Applications
Current Protein & Peptide Science, 2023 · PMID: 36464872
Comprehensive review: Tb4 comprises 70-80% of all beta-thymosins in the human body. Clinical applications span organ preservation (kidney, liver, heart, brain, intestine), hair loss, skin trauma, and corneal repair. Maps the full spectrum: inflammation regulation, angiogenesis, wound repair, hair follicle regeneration, nervous system development.
Important context
Benefits reported in clinical trials represent average outcomes across study populations. Individual results vary based on genetics, dosage, duration, and lifestyle factors. This compound is not FDA-approved for human use. Benefits described are based on research data and should not be interpreted as therapeutic claims.
Related peptides
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.